KMT2A and acute myeloid leukemia: Though immense efforts have been exerted in developing novel therapeutic strategies in the past decades, the standard chemotherapy with intensive administration of chemotherapeutic drugs, e.g. the “7 + 3” regimen (i.e. combined treatment of anthracycline (daunorubicin or doxorubicin) and cytarabine (Ara-C)), remains the main therapeutic approach for treating AML, including MLL-rearranged AML5–8.